Abstract:Introduction: RWE is increasingly used in the oncology community, particularly following the 2016 21st Century Cures Act. A recent analysis of RWE presented at ASCO reported a significant increase in relative frequency of RWE abstracts from 2011-2021[1]. We conducted a similar trend analysis of RWE presented at AACR and predictive factors associated with publication. Methods: EMBASE was queried for abstracts presented at AACR 2013-2022, using terms related to study designs and methodologies that employ use of RWE. Details on study design, location, data source, patient number, cancer site, analytical approach, endpoints, and presentation type (oral vs. poster) were extracted and analyzed. Searches in Google Scholar identified published manuscripts associated with each abstract. The Cochran-Armitage trend test and Monte-Carlo estimation of the exact test were used to detect trends over time; p-values are provided for descriptive purposes. Relative risk ratios were calculated to determine statistically significant predictors of publication. Results: Of 56,920 total abstracts presented at AACR from 2013-2022, 611 (1.1%) RWE abstracts were identified. The proportion of presented abstracts with RWE increased from 0.6% in 2013 to 2.0% in 2022 (p<0.001). Among the RWE abstracts, use of electronic medical record (2013: 0% vs. 2022: 9.3%; p=0.002) and genomics databases (i.e., GENIE) (2013: 0% vs. 2022: 8.3%; p=0.006) increased over time. While majority of RWE abstracts were presented as posters (95.9%), the proportion of oral presentations increased in the last decade (2013: 0.0% vs. 2022: 3.7%; p=0.005). s with sample sizes <500 decreased significantly over time (p=0.002); those with sample sizes 5,000-<50,000 increased significantly over time (p=0.001). The proportion of abstracts including multiple cancer sites (vs. single-site) increased from 5.1% in 2013 to 20.4% in 2022 (p<0.001). The most common cancer sites were lung, breast, and colorectal. Statistically significant factors associated with publishing an abstract into a manuscript included study sample size 500-<5,000 or ≥100,000, inferential statistics (vs. descriptive), propensity score matching, and effectiveness or disease burden endpoints.Conclusion: RWE studies presented at AACR increased in the recent decade, with more robust study designs, incorporation of novel clinico-genomic databases such as GENIE, and advanced analytical approaches. These findings suggest the value of RWE has been increasingly recognized by the oncology research community and that RWE is being used to provide critical insights and inform patient care. Given FDA's recent guidance on RWE to support regulatory decision-making, this trend will likely continue. [1] Azad Fet al. Longitudinal trends of real-world evidence (RWE) reporting in oncology conferences: An 11-year ASCO Annual Meeting analysis. Citation Format: Jihong Zong, Lauren C. Bylsma, Orsolya Lunacsek, Jon Fryzek. Real-world evidence (RWE) presented at AACR annual meetings: A 10-year trend analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6464.

Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshop

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Using Real-World Evidence To Support The Fda Regulatory Approval: Methodological Considerations

Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop

The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Abstract 6464: Real-world evidence (RWE) presented at AACR annual meetings: A 10-year trend analysis

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective

Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative

Real-World Evidence: A Primer

Linking clinical trial participants to their U.S. real-world data through tokenization: A practical guide

The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

Collaborative Real-World Evidence Among Regulators: Lessons and Perspectives

Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals

Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease

Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process